In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
The company expects that this development could improve the strength of its application to the FDA for new drug approval
RPG Life Sciences has reported total income of Rs. 155.41 crores during the period ended September 30, 2023
The company has reported total income of Rs. 486.16 crores during the period ended September 30, 2023
The company is confident of addressing all the observations within the stipulated time
Syngene gains access to ERS Genomics' foundational CRISPR/Cas9 patent portfolio, ushering in a new era of technical innovation in India for its global partners
New Molecular biology lab launched, AIIA increased its work scope in form of MoUs
Aarti Drugs has reported total income of Rs. 642.22 crores during the period ended September 30, 2023
Laurus Labs has reported total income of Rs. 1226.23 crores during the period ended September 30, 2023
Three-point improvement achieved in Sex Ratio at Birth from 904 in 2017-19 to 907 in 2018-20
Subscribe To Our Newsletter & Stay Updated
